RareWays is a research directory. It helps you understand the science. It is not medical advice. Always discuss your care options with your healthcare team.
Coverage: 2020-01-01 onwards, with up to 300 results per query from PubMed and Europe PMC and separate limits on other sources. This is a selected index, not a complete literature search.
Updates are delayed or unverified. Check original sources for the latest information.
Your saved research and appointment questionsView recorded trial and retraction changes
Insulinoma: Research Summary
Printed from RareWays (rareways.org)
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
68Ga-DOTA-exendin-4 PET/CT for insulinoma localization in patients with negative or inconclusive conventional imaging.
Fricke Julia G et al., The Journal of clinical endocrinology and metabolism (16 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42168767/
- 2.
Ersodetug for refractory hypoglycemia due to malignant insulin-secreting tumors.
Strosberg Jonathan et al., The Journal of clinical endocrinology and metabolism (16 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42557582/
- 3.
Aspek Diagnosis dan Tata Laksana Pancretic Neuroendocrine Tumor dengan Kecurigaan Insulinoma
Nicolaus Lizu Tallo et al., ANATOMICA MEDICAL JOURNAL | AMJ (14 October 2026)
https://doi.org/10.30596/amj.v9i3.30938
- 4.
Endoscopic Ultrasound-Guided Ethanol Ablation for Benign Insulinoma: A Single-Centre Experience and Literature Review.
Wu Yuchao et al., Clinical endocrinology (14 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42875992/
- 5.
Insulinoma With Secondary Adrenal Dysfunction: Clinical Characteristics and High-Risk Factors.
Li Mengni et al., Clinical endocrinology (7 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42841263/
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Insulinoma
Insulinoma is a rare tumour of the pancreas that produces too much insulin. This can cause repeated episodes of low blood sugar, leading to sweating, confusion, blackouts or seizures. Most insulinomas are non-cancerous. Surgery to remove the tumour is the main treatment, and medicines can help control blood sugar for people who cannot have surgery.
This overview is general information, not an individual medical assessment. Research is selected automatically and may include mismatches. How we select and explain research.
Most Recent Research
CONTEXT: Insulinomas are the main cause of endogenous hyperinsulinemic hypoglycemia (EHH) in adults, with surgery as the only cure. Pancreas-preserving surgery is preferred, making precise preoperative localization crucial. GLP-1R-targeted imaging, such as [68Ga]Ga-DOTA-exendin-4 PET/CT, outperforms other imaging procedures for insulinoma localization. OBJECTIVE: To investigate the performance and clinical impact of [68Ga]Ga-DOTA-exendin-4 PET/CT for the detection of insulinomas in patients with EHH and prior negative or inconclusive conventional imaging. METHODS: In this retrospective, real-world, dual-center imaging study, 101 patients with biochemically proven EHH and/or a positive Whipple's triad underwent [68Ga]Ga-DOTA-exendin-4 PET/CT at two tertiary centers between April 2017 and March 2024. Among these, 58 patients with prior negative or inconclusive conventional imaging constituted the primary analysis cohort. Endpoints: Insulinoma detection rate and sensitivity by [68Ga]Ga-DOTA-exendin-4 PET/CT after negative or inconclusive conventional imaging and impact on clinical management. RESULTS: Among the 58 patients with prior negative or inconclusive conventional imaging, [68Ga]Ga-DOTA-exendin-4 PET/CT was positive in 42 patients, corresponding to a detection rate of 72% (95% CI, 59-83%). Thirty patients subsequently underwent PET/CT-guided surgery. Overall, 32 patients had histological verification (including two PET/CT-negative cases), corresponding to a sensitivity of 93.8% (95% CI, 79-99%). CONCLUSION: In real-world clinical practice, [68Ga]Ga-DOTA-exendin-4 PET/CT provides a high detection rate of 72% for localizing insulinomas, including one case of diffuse nesidioblastosis in patients with EHH and prior negative or inconclusive conventional imaging, thereby enabling PET/CT-guided surgical approaches. These findings underscore the substantial clinical impact of GLP-1R-targeted PET/CT on patient management and prognosis.
Common Questions
What is Insulinoma?
Insulinoma is a rare tumour of the pancreas that produces too much insulin. This can cause repeated episodes of low blood sugar, leading to sweating, confusion, blackouts or seizures. Most insulinomas are non-cancerous. Surgery to remove the tumour is the main treatment, and medicines can help control blood sugar for people who cannot have surgery.
How many clinical trials are available for Insulinoma?
RareWays currently indexes 35 clinical trials for Insulinoma, of which 2 are actively recruiting. These counts cover indexed trials across countries, not just your country. An Australian site does not necessarily mean that site is recruiting. Check locations, eligibility and current availability with the study team.
Where does the research data for Insulinoma come from?
RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is refreshed automatically every day. All articles and trials link directly to their original sources.
Get research updates
Monthly email when new findings are published for Insulinoma.
Your email and selected disease are stored for these updates. Unsubscribe any time. Privacy and deletion.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.